GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (LTS:0MGB) » Definitions » Profitability Rank

Genmab A/S (LTS:0MGB) Profitability Rank : 10 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Genmab A/S Profitability Rank?

Genmab A/S has the Profitability Rank of 10. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Genmab A/S's Operating Margin % for the quarter that ended in Mar. 2024 was 19.33%. As of today, Genmab A/S's Piotroski F-Score is 4.


Competitive Comparison of Genmab A/S's Profitability Rank

For the Biotechnology subindustry, Genmab A/S's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Profitability Rank falls into.



Genmab A/S Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Genmab A/S has the Profitability Rank of 10. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genmab A/S's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=801 / 4143
=19.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Genmab A/S has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Genmab A/S operating margin has been in a 5-year decline. The average rate of decline per year is -7.4%.

4. Consistency of the profitability

5. Predictability Rank


Genmab A/S Profitability Rank Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (LTS:0MGB) Business Description

Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (LTS:0MGB) Headlines

No Headlines